NCT05349474CompletedEarly phase 1
Metformin Treatment in Progressive Multiple Sclerosis
A Double-blind, Placebo Controlled Trial of Metformin Treatment in Progressive Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 22 Jul 2025
Brief summary (registry, in English)
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 21 Apr 2022
- Start date
- Apr 2022
- Primary completion date
- May 2025
- Lead sponsor
- University of California, Los Angeles
- Diseases
- Multiple sclerosis
- NCT number
- NCT05349474
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 23
- From Apr 2022 to the primary completion date, May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Clinical relapse in prior 12 months
- New T2 lesion or gadolinium enhancing lesion in prior 12 months
- Glucocorticoid use in prior six months outside the context of premedication for disease modifying treatment
- Changes in disease modifying therapy in prior three months
- Prior poor reaction to metformin
- Concomitant use of drugs with drug-drug interactions with metformin
- Previous adverse effect with metformin treatment
Other illness
- Plans to change current disease modifying therapy
- Congestive heart failure
Lab values
- Renal dysfunction (GFR \< 60)
- Hepatic dysfunction (AST or ALT \> 1.5 x upper limit of normal)
Other
- Contraindication to MRI, inability to tolerate MRI
- Use of metformin for any other indication
- B12 deficiency
- Alcohol abuse
- Metabolic acidosis
- Females who are pregnant or who plan to become pregnant during the 12 months of enrollment, or who wish to breastfeed during any part of the 12 months of enrollment
Who the study is looking for
- Patient signed informed consent.
- Age 30-65
- Primary Progressive Multiple Sclerosis or Secondary Progressive Multiple Sclerosis as defined by the 2017 McDonald Criteria
- Intent to maintain current MS disease modifying treatment through the trial duration
Age in the registry: 30 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California, Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.